Latest revenue
$106.16B
as of 2025-12-31
Latest net income
$1.19B
as of 2025-12-31
Net margin
1.1%
as of 2025-12-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $92.09B
- Enterprise value
- $98.11B
- P/E (trailing)
- 19.3×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.4%
- 52-wk high
- $999.00
- 52-wk low
- $637.00
- Beta
- —
- Shares out
- 120.2M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
McKesson distributes prescription drugs and medical supplies, moving pharmaceuticals from manufacturers to pharmacies, hospitals, and physician practices across North America and Europe. The company earns the vast majority of its $307 billion nine-month revenue from low-margin pharmaceutical distribution, supplemented by higher-margin oncology services, prescription technology, and medical-surgical products. McKesson just reorganized into four segments and is leaning harder into oncology, spending $3.4 billion on acquisitions this year while revenue grew 14% and operating income jumped 43%.
Generated from MCK's filing dated 2026-05-08
Key risks
- Outstanding opioid litigation liabilities of $5.1 billion long-term, with $669 million paid in nine months; settlements continue to drain cash flow.
- Stockholders' deficit of $901 million with razor-thin 1.2% gross margin; minor cost-of-sales shocks could materially compress $4.1B operating income.
- Customer concentration and acquisition risk: $3.4B in acquisitions added $2.7B intangibles/goodwill; cash fell to $2.96B from $5.69B in nine months.
Generated from MCK's filing dated 2026-05-08
Profitability
Gross margin
3.6%
2.8%Operating margin
1.5%
25.0%Net margin
1.2%
28.6%Return on equity
-219.2%
38.0%Return on assets
5.8%
31.9%Leverage
Debt / equity
-38.90×
4.5%Long-term debt / equity
-2.42×
12.5%Debt / assets
102.6%
0.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $96.30B | +6.0% | $1.68B | +33.5% | 1.7% |
Q4 2025 2025-12-31 | $106.16B | +11.4% | $1.19B | +34.9% | 1.1% |
Q3 2025 2025-09-30 | $103.15B | +10.1% | $1.11B | +360.6% | 1.1% |
Q2 2025 2025-06-30 | $97.83B | +23.4% | $784.0M | -14.3% | 0.8% |
Q1 2025 2025-03-31 | $90.82B | +18.9% | $1.26B | +59.3% | 1.4% |
Q4 2024 2024-12-31 | $95.29B | +17.8% | $879.0M | +49.2% | 0.9% |
Q3 2024 2024-09-30 | $93.65B | +21.3% | $241.0M | -63.7% | 0.3% |
Q2 2024 2024-06-30 | $79.28B | +6.4% | $915.0M | -4.5% | 1.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122
Your notes
Keep private notes on MCK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$53.2M
Net activity
−$53.2M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns MCK
Institutional value
$27.58B
Total shares held
32.8M
Distinct holders
731
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 8.0M | $6.89B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.9M | $2.49B | — | New |
| 3 | Invesco Ltd. | 1.5M | $1.29B | — | New |
| 4 | Boston Partners | 1.2M | $1.00B | — | New |
| 5 | WCM INVESTMENT MANAGEMENT, LLC | 932.1K | $801.8M | — | New |
| 6 | Legal & General Group Plc | 916.7K | $793.3M | — | New |
| 7 | Bank of New York Mellon Corp | 825.6K | $714.5M | — | New |
| 8 | TD ASSET MANAGEMENT INC | 710.4K | $614.8M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 705.6K | $610.6M | — | New |
| 10 | Nuveen, LLC | 612.0K | $529.6M | — | New |
| 11 | UBS Group AG | 609.5K | $527.4M | — | New |
| 12 | WELLS FARGO & COMPANY/MN | 459.7K | $397.8M | — | New |
| 13 | DEUTSCHE BANK AG\ | 459.1K | $397.3M | — | New |
| 14 | ENVESTNET ASSET MANAGEMENT INC | 424.8K | $367.6M | — | New |
| 15 | Voya Investment Management LLC | 420.2K | $363.1M | — | New |
| 16 | National Pension Service | 396.2K | $342.9M | — | New |
| 17 | Swiss National Bank | 362.3K | $313.5M | — | New |
| 18 | DIMENSIONAL FUND ADVISORS LP | 356.4K | $308.4M | — | New |
| 19 | California Public Employees Retirement System | 324.0K | $280.4M | — | New |
| 20 | Sumitomo Mitsui Trust Group, Inc. | 281.1K | $243.3M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Gross margin compressed to 3.47% from 3.61% YoY despite revenue growing 14%—how much is GLP-1 mix dilution versus pricing pressure from larger PBM customers?
- 2
You deployed $3.4B on acquisitions and intangibles jumped from $1.5B to $4.2B—quantify expected accretion and disclose the specific deals driving the $802M redeemable NCI.
- 3
Long-term litigation liabilities still sit at $5.1B with $669M paid this year—what's your remaining opioid cash outflow schedule and any new exposure from pending state actions?
Refreshed when MCK files a new report · last from 2026-05-08